宫腔镜下诊治人流术后宫腔粘连64例临床分析

目的探讨宫腔镜在人流术后宫腔粘连中的诊治效果。方法选择2012-12~2014-12该院妇科人流术后病理确诊为宫腔粘连患者64例,比较超声、子宫输卵管造影和宫腔镜在该病中的检出率,确诊后均选择宫腔镜下宫腔粘连分离术治疗,观察分析疗效。结果超声诊断符合率为82.81%,子宫输卵管造影诊断符合率为87.50%,宫腔镜诊断符合率为100%,宫腔镜检出率明显优于超声、子宫输卵管造影(P0.05)。64例术后恢复总有效率为95.31%。宫腔粘连术后评分为(1.16±0.86)分,雌二醇和卵泡刺激素水平分别为(107.60±28.60)pg/ml和(5.82±0.92)m IU/ml,与术前比较差异具有统计学意义(P0.05)。结论宫腔镜是人流术后宫腔粘连有效的诊断方法。宫腔镜下宫腔粘连分离术是有效的治疗方法。     

子宫动脉栓塞联合宫腔镜清宫术在剖宫产术后切口妊娠中的应用

目的 观察子宫动脉栓塞联合宫腔镜清宫术在剖宫产术后切口妊娠中的应用.方法 86例剖宫产后切口妊娠的患者按照数字表法随机分为两组,观察组43例,对照组43例,观察组采用子宫动脉栓塞术联合宫腔镜治疗,对照组采用氨甲喋呤（MTX）肌内注射治疗.观察出血量、住院时间、血β-HCG降至正常的时间及不良反应等.结果 观察组患者的出血量、住院时间、血β-HCG降至正常的时间及不良反应例数均低于对照组（P＜0.05）.结论 子宫动脉栓塞术联合宫腔镜治疗剖宫产术后切口妊娠疗效显著,不良反应少.     

宫腔镜电切术、子宫动脉栓塞术治疗子宫肌瘤疗效对比

目的 比较官腔镜电切术与子宫动脉栓塞术治疗子宫肌瘤的疗效.方法 100例子宫肌瘤患者随机分为A、B组,各50例,分别采用官腔镜电切术和子宫动脉栓塞术治疗.结果 两组患者手术均获成功.A组手术时间为(65.23±11.04) min,低于B组的(98.36±15.22) min,P＜0.01.A组住院时间(6.35 ±0.01)d,与B组的(6.42±0.02)d相比,P＞0.05.治疗12个月后,A组患者肌瘤均消失,B组7例患者瘤体缩小、5例患者肌瘤复发.A、B组手术治愈率分别为100％、78％,两组相比,P＜0.01.结论 官腔镜电切术治疗子宫肌瘤疗效优于子宫动脉栓塞术.     

子宫动脉栓塞治疗子宫肌瘤的术后护理

20 0 0～ 2 0 0 2年 ,我院对 2 6例子宫肌瘤患者进行了子宫动脉栓塞治疗。现将术后护理体会介绍如下。临床资料 :本组 2 6例子宫肌瘤患者的年龄为 2 9～ 4 7岁 ,平均 4 0 .2岁 ;临床表现有月经过多、不同程度的下腹痛、下坠感及贫血等。 2 5例有生育史。其中 16例为单发性肌瘤 ,10例为多发性肌瘤 ,肌瘤直径 2 .2～ 8.5 cm。介入治疗 :在数字减影血管造影 (DSA)机监视下 ,采用 Seldinger技术 ,经股动脉穿刺插管 ,将导管超选择插入对侧子宫动脉。待造影证实为肌瘤供血动脉后 ,用栓塞剂葡聚糖微球或平阳霉素碘油乳剂栓塞供血动脉。在肌瘤血管…     

子宫动脉栓塞术治疗子宫肌瘤62例体会

2003年3月～2005年9月,我们应用子宫动脉栓塞（TUAE）治疗子宫肌瘤62例。现分析并报告如下。     

经导管子宫动脉栓塞术治疗子宫腺肌病临床观察

目的探讨经导管子宫动脉栓塞术（TUAE）治疗子宫腺肌病的疗效及安全性。方法对加例子宫腺肌病患者采用Seldlnger技术行经导管TUAE治疗。结果术后痛经完全缓解25例,明显缓鼹14例,6个月后复发1例。月经量减少至术前的55．2％±17．5％,月经周期无明显变化。栓塞后6个月,腺肌瘤体积与子宫体积平均缩小48．1％和39．6％,28例12个月平均缩小60．3％和44．8％。术后彩超检查显示子宫肌层及病灶内血流信号明显减少,后者减少更为明显。结论TUAE治疗子宫腺肌病疗效可靠,安全性高。     

经导管子宫动脉栓塞术治疗子宫肌瘤42例

2000年5月～2004年5月，我们采用经导管子宫动脉栓塞术（TUAE）治疗42例子宫肌瘤患者，疗效良好。现报告如下。     

子宫动脉栓塞术与子宫切除术治疗产后出血临床疗效比较

目的探讨子宫动脉栓塞术与子宫切除术治疗产后出血的临床疗效及价值。方法将非手术治疗无效的产后出血患者53例随机分为观察组(29例)和对照组(24例),观察组应用子宫动脉栓塞术治疗,对照组予以子宫切除术治疗。结果观察组治愈率为86.2%,无效率为3.4%,对照组治愈率为91.7%,无效率为0.0%,两组疗效比较差异无统计学意义(P0.05);两组并发症发生率比较差异无统计学意义(P0.05);术后随访观察组生活质量优于对照组(P0.05)。结论子宫动脉栓塞术处理非手术治疗无效的产后出血疗效显著,快捷,创伤轻,副作用少,有较大的临床推广价值。     

子宫动脉栓塞术在子宫肌瘤治疗中的应用进展

子宫肌瘤是女性最常见的良性肿瘤,好发于中年妇女,发病率为35%~45%[1],传统治疗方法包括肌瘤挖除术、子宫切除术、药物治疗、肌溶解、冷冻等,最近新兴的治疗方法包括子宫动脉栓塞、高能聚焦超声刀等。子宫动脉栓塞术（UAE）于90年代由法国医师Ravina等首先应用于子宫肌瘤的治疗,并在后续治疗中逐渐发展完善。现对UAE在子宫肌瘤中的应用进展综述如下。     

延长球囊子宫支架放置时间治疗中重度宫腔粘连的疗效及安全性分析

目的探讨延长球囊子宫支架放置时间治疗中重度宫腔粘连分离术后预防再次粘连的临床效果及安全性。方法选择2016-01~2018-12在该院诊断为中重度宫腔粘连并行粘连分离术的患者210例,采用随机数字表法将其分为对照组和观察组,每组105例。对照组在予宫腔镜宫腔粘连分离术后放置球囊子宫支架,1周后整体取出。观察组在予宫腔镜宫腔粘连分离术后放置球囊子宫支架,1周后剪球囊尾管放出球囊内液体,留置球囊支架,术后第2次月经干净后取出。比较两组术后宫腔粘连、月经恢复、并发症的发生情况。结果对照组术后第1个月月经改善率为72.38%,观察组为77.14%,两组差异无统计学意义(P>0.05);但两组术后第2个月、第3个月及第6个月观察组的月经改善率高于对照组,差异有统计学意义(P<0.05)。对照组宫腔粘连改善有效率为76.19%,观察组为87.62%,差异有统计学意义(P<0.05)。观察组术后并发症发生率高于对照组,差异有统计学意义(9.52%vs 0.00%,χ2=10.500,P=0.001)。结论延长球囊子宫支架放置时间可以改善宫腔粘连,改善月经量,延长放置球囊子宫支架虽存在一定的风险,但经处理后可治愈,是相对安全的,临床工作中仍需严密观察及随访。     

Comparison of D&C and hysteroscopy after UAE in the treatment of cesarean scar pregnancy: A case-control study

Cesarean scar pregnancy (CSP) stands for the severe complication secondary to cesarean section, and its incidence shows an increasing trend recently. However, no consensus has been reached about the CSP treatment. This study aims to explore the necessity of hysteroscopy (H/S) after preventive uterine artery embolization (UAE).A case-control report. The childbearing CSP patients with a cesarean section history were evaluated by ultrasonography, with a gestational age of less than 10 weeks. Thirty-four patients receiving dilation and curettage (D&C) after UAE were enrolled into the D&C group, whereas 46 undergoing H/S and curettage after UAE were enrolled into the H/S group.Differences in success rate and decrease in the β-hCG level in serum on the second day of surgery were not significantly different between D&C and H/S groups (P > .05). Also, differences in side effect rate (except for the anesthesia-related side effects), intraoperative blood loss amount, postoperative bleeding time, and total length of hospital stay were not significant between 2 groups (P > .05). Compared with D&C group, H/S group had decreased postoperative length of hospital stay (P < .05), increased hospitalization cost (P < .05), and significantly elevated time of CSP mass disappearance (P < .05). In addition, 8 (18.19%) patients in H/S group developed anesthesia-related side effects.This study reveals no obvious difference between UAE + D&C and UAE + H/S in terms of the clinical efficacy and safety, except for the time of CSP mass disappearance and anesthesia-related side effects. The hospitalization cost is more expensive for UAE + H/S, but the postoperative length of stay is shorter for UAE + H/S. UAE + H/S is associated with the risk of anesthesia-associated side effects.     

8Spheres conformal microspheres as embolic agents for symptomatic uterine leiomyoma therapy in uterine artery embolization (UAE): A prospective clinical trial

To evaluate the treatment efficacy of uterine artery embolization (UAE) using 8Spheres conformal microspheres for symptomatic uterine leiomyoma. In this prospective observational study, 15 patients were enrolled and underwent UAE by 2 experienced interventionalists from September 1, 2018, to September 1, 2019. All patients underwent menstrual bleeding scores, the symptom severity domain of the Uterine Fibroid Symptom and Quality of Life questionnaire scores (with lower scores indicating mild symptoms), pelvic contrast-enhanced magnetic resonance imaging, ovarian reserve tests (estradiol, prolactin, testosterone, follicle-stimulating, luteinizing, and progesterone), and other appropriate preoperative examinations within 1 week before UAE. During follow-up, menstrual bleeding scores and the symptom severity domain of the Uterine Fibroid Symptom and Quality of Life questionnaire scores were recorded at 1, 3, 6, and 12 months after UAE to assess the efficacy of symptomatic uterine leiomyoma. Pelvic contrast-enhanced magnetic resonance imaging was performed 6 months after the interventional therapy. Biomarkers of ovarian reserve function were reviewed at 6 and 12 months after treatment. All 15 patients successfully underwent UAE, without severe adverse effects. Six patients experienced abdominal pain, nausea, or vomiting, all of which improved significantly after symptomatic treatment. The menstrual bleeding scores declined from baseline (350.2 ± 61.9 mL) to (131.8 ± 42.7 mL), (140.3 ± 42.4 mL), (68.0 ± 22.8 mL), and (64.43 ± 17.0 mL) at 1, 3, 6, and 12 months, respectively. The symptom severity domain scores at 1, 3, 6, and 12 months postoperatively were significantly lower and statistically significant compared to the preoperative scores. The uterus and dominant leiomyoma volumes decreased from baseline (340.0 ± 35.8 cm³), (100.6 ± 24.3 cm³) to (266.6 ± 30.9 cm³), (56.1 ± 17.3 cm³) at 6 months after UAE, respectively. Moreover, the ratio of leiomyoma volumes and uterus decreased from (27.4 ± 4.5%) to (18.7 ± 3.9%). At the same time, there was no significant effect on changes in the biomarkers of ovarian reserve levels. Only the changes in testosterone levels before and after UAE were statistically significant (P < .05). 8Spheres conformal microspheres are ideal embolic agents for UAE therapy. This study showed that 8Spheres conformal microsphere embolization for symptomatic uterine leiomyoma could effectively relieve heavy menstrual bleeding, improve the symptom severity of patients, reduce the volume of leiomyoma, and have no significant effect on ovarian reserve function.     

Diagnosis and treatment of uterine artery pseudoaneurysm: Case series and literature review

Background:Uterine artery pseudoaneurysm (UAP) is a rare but potentially life-threatening cause of hemorrhage. Nonetheless, its knowledge could be insufficient among obstetricians, gynecologists, and radiologists. We aimed to clarify the clinical characteristics, management, and outcomes of UAP.Methods:We retrospectively analyzed nine female patients diagnosed with UAP at our institute between 2013 and 2020.Results:Seven cases presented with a history of traumatic surgery including cesarean section, dilation and curettage, laparoscopic myomectomy, and cervical conization. Two cases occurred after spontaneous vaginal delivery and second-trimester pregnancy termination. The main symptom was heavy/massive/prolonged vaginal bleeding. All patients were first evaluated by color Doppler ultrasonography and three cases were confirmed by magnetic resonance imaging. Severn patients underwent transarterial embolization (TAE) of the uterine arteries, and two were managed conservatively. All patients had good outcomes.Conclusions:UAP can develop after traumatic pelvic operations and non-traumatic delivery/abortion. It may be more common than previously considered. The risk of rupture may be correlated with multiple factors other than the mass size. TAE of the uterine artery could be an effective management strategy for ruptured UAP. However, some cases can resolve spontaneously without TAE, suggesting that conservative management can be employed in some women.     

大剂量雌激素对中重度宫腔粘连预后的影响

目的探讨大剂量雌激素对中重度宫腔粘连(IUA)预后的影响及子宫内膜雌激素受体(ER)与预后的相关性。方法中重度IUA患者60例,宫腔镜IUA分离术(TCRA)术后辅助大剂量雌激素(戊酸雌二醇10 mg/d)治疗。实验组30例,雌激素连续治疗3个月。对照组30例,雌激素人工周期治疗3个月。术后1、3个月行宫腔镜检查。结果随访6～12个月,术后3个月宫腔形态恢复总有效率为88.3%(53/60),其中实验组90%(治愈46.7%、好转43.3%)、对照组86.7%(治愈46.7%、好转40%)(P>0.05)。术后6个月月经改善总有效率为76.7%(46/60),其中实验组90%(治愈46.7%、好转43.3%)、对照组63.3%(治愈23.3%、好转40%)(P<0.05)。术后宫腔形态恢复有效率与ER阳性率呈正相关(r=0.339,P<0.01)。术后24例试孕,已妊娠10例(41.7%)。结论中重度IUA分离术后辅以大剂量雌激素治疗能有效提高治愈率,连续用药优于人工周期治疗。随着子宫内膜ER阳性率的增加,预后效果明显增加。     

透明质酸钠宫腔注入及优思明口服对稽留流产患者术后宫腔粘连的预防效果

目的：观察透明质酸钠宫腔注入及优思明口服减轻稽留流产患者术后宫腔粘连的效果及安全性。方法将800例因稽留流产而行清宫手术的患者按随机数字表法分为实验A、B、C组及对照组各200例,四组均由同一组高年资主治医师严格按照操作规则进行全程超导可视无痛清宫术（术前用药均为复方米非司酮及米索前列醇）,其中实验B组术毕宫腔注入透明质酸钠1 mL,实验C组术后即刻开始口服优思明1片/d,连续21 d,实验A组同时应用上述两种方法。观察各组手术情况、月经量变化及宫腔粘连发生情况、药物不良反应。结果各组均未发生术中并发症,手术时间无显著差异;各实验组月经量减少及宫腔粘连发生率均低于对照组,尤以实验A组为著（P均＜0．05）。实验A组和C组各有1例出现轻微头晕、恶心、乳房胀痛及术后阴道流血、月经间期阴道点滴出血等,均自行好转;无体质量增加者。结论透明质酸钠宫腔注入联合优思明口服可显著降低稽留流产患者术后宫腔粘连发生率,且安全性高。     

支气管动脉栓塞术后再咯血原因及治疗对策

目的探讨支气管动脉栓塞术（BAE）后再咯血的原因及相应的治疗对策。方法分析389例行支气管动脉栓塞术后发生再咯血的54例患者的咯血原因及治疗结果。结果54例再咯血中,34例为原有病变进展,占63．0％,DSA表现为出现新的出血灶和／或侧支循环形成。20例原因为原有病变血管再通,占37．0％。再次BAE术后治愈47例,占87．0％。结论支气管动脉栓塞术后应积极地治疗基础疾病防止原有病变进展。在支气管动脉栓塞术操作过程中防止漏栓供血动脉,并注意操作技巧,选择适当的栓塞材料。